Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The pharmacological management of osteoporosis.

Literature DB >> 21568234

The pharmacological management of osteoporosis.

Abstract

Pharmacotherapy is effective in decreasing the incidence of osteoporotic fracture, morbidity, and mortality. This benefit is pronounced in patients at highest risk for fracture: those with prior osteoporotic fracture, very low bone mineral density, or receiving chronic corticosteroid treatment. We review the best pharmacotherapeutic options currently available for treating osteoporosis.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21568234 PMCID： PMC3597219

Source DB: PubMed Journal: Mo Med ISSN： 0026-6620

25 in total

1. Teriparatide (forteo) for osteoporsis.

Authors:
Journal: Med Lett Drugs Ther Date: 2003-02-03 Impact factor: 1.909

2. A once-yearly IV bisphosphonate for osteoporosis.

Authors:
Journal: Med Lett Drugs Ther Date: 2007-11-05 Impact factor: 1.909

3. Drugs for postmenopausal osteoporosis.

Authors:
Journal: Treat Guidel Med Lett Date: 2008-10

4. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.

Authors: Elizabeth Barrett-Connor; Lori Mosca; Peter Collins; Mary Jane Geiger; Deborah Grady; Marcel Kornitzer; Michelle A McNabb; Nanette K Wenger
Journal: N Engl J Med Date: 2006-07-13 Impact factor: 91.245

5. Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density.

Authors: J S Adams; V Kantorovich; C Wu; M Javanbakht; B W Hollis
Journal: J Clin Endocrinol Metab Date: 1999-08 Impact factor: 5.958

Review 6. Use of oral corticosteroids and risk of fractures.

Authors: T P Van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal: J Bone Miner Res Date: 2000-06 Impact factor: 6.741

Review 7. The role of dual energy X-ray absorptiometry of lumbar spine and proximal femur in the diagnosis and follow-up of osteoporosis.

Authors: R Rizzoli; D Slosman; J P Bonjour
Journal: Am J Med Date: 1995-02-27 Impact factor: 4.965

Review 8. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes.

Authors: Heike A Bischoff-Ferrari
Journal: Adv Exp Med Biol Date: 2008 Impact factor: 2.622

9. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors: Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal: J Bone Miner Res Date: 2007-10 Impact factor: 6.741

6. Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex.

Authors: Seung Rim Hwang; Dong-Hyun Seo; Youngro Byun; Jin Woo Park
Journal: Int J Nanomedicine Date: 2016-08-31

6 in total

The pharmacological management of osteoporosis.

1. Teriparatide (forteo) for osteoporsis.

2. A once-yearly IV bisphosphonate for osteoporosis.

3. Drugs for postmenopausal osteoporosis.

4. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.

5. Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density.

Review 6. Use of oral corticosteroids and risk of fractures.

Review 7. The role of dual energy X-ray absorptiometry of lumbar spine and proximal femur in the diagnosis and follow-up of osteoporosis.

Review 8. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes.

9. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

10. High-trauma fractures and low bone mineral density in older women and men.

1. Impact and risk factors of post-stroke bone fracture.

2. A Vitronectin-Derived Peptide Restores Ovariectomy-Induced Bone Loss by Dual Regulation of Bone Remodeling.

3. Three generations of treatments for osteoporotic vertebral fractures: what is the evidence?

4. Comparative analysis of vertebroplasty and kyphoplasty for osteoporotic vertebral compression fractures.

Review 5. Non-neuronal Role of Acetylcholinesterase in Bone Development and Degeneration.

6. Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex.